(Sharecast News) - EKF Diagnostics said in an update on Tuesday that trading so far in 2026 remained in line with management expectations, supported by strong cash generation and continued momentum in its hematology and life sciences businesses.
The AIM-listed diagnostics company, which was holding its annual general meeting, said the...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE